Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide with continued versus intermittent ADT after PSA response in metastatic castration-sensitive prostate cancer
2022-502686-24-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate cancer (PCa) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: 18-month radiographic progression-free survival rate and 18-month percent change in severity adjusted hot flash score. Planned start Sep 2023; status: authorised.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2022-502686-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502686-24-00.